Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus MOTRIN IB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus MOTRIN IB.
JUNIOR STRENGTH MOTRIN vs MOTRIN IB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
None Documented
None Documented
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Category C
Category C
NSAID Analgesic
NSAID Analgesic